
FDA Approves Ritlecitinib, a Breakthrough Hair Loss Drug for Alopecia Patients
The United States Food and Drug Administration (FDA) has approved a new oral drug called ritlecitinib for the treatment of severe hair loss in patients with alopecia areata. In clinical trials, the medication showed promising results, with up to 80% of hair loss on the scalp being reversed in some patients. Ritlecitinib is effective and well-tolerated, making it a significant treatment option for severe alopecia, including cases in children. The drug works by dampening the immune system's overactive response, promoting hair regrowth. However, patients may be more susceptible to infections and sicknesses due to its impact on the immune system.
